Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference
February 08 2018 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”)
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company
developing differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, Rett syndrome and other central nervous system
(CNS) diseases, announced today that its President & Chief
Executive Officer, Christopher U. Missling, PhD, will present a
company update at the 2018 BIO CEO & Investor Conference on
Monday, February 12, 2018 at 9:45 a.m. ET. The conference will be
held at the New York Marriott Marquis.
A live webcast of the presentation will be available on
http://www.veracast.com/webcasts/bio/ceoinvestor2018/28108101942.cfm.
A replay will be available via www.anavex.com and will be
accessible for three months following the presentation.
Investors or potential partners attending the conference who
wish to meet with Anavex Life Sciences management should contact
the BIO Partnering Team at biopartnering@bio.org.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX®2-73, recently completed a successful a Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors. Preclinical studies demonstrated
its potential to halt and/or reverse the course of Alzheimer’s
disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research has awarded Anavex a research grant to develop ANAVEX®2-73
for the treatment of Parkinson’s disease. The grant fully funds a
preclinical study, which could justify moving ANAVEX®2-73 into a
Parkinson’s disease clinical trial. ANAVEX®3-71, targeting sigma-1
and M1 muscarinic receptors, is a promising preclinical drug
candidate demonstrating disease modifications against the major
Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, and also with
beneficial effects on neuroinflammation and mitochondrial
dysfunctions. Further information is available at www.anavex.com.
You can also connect with the company on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors & Media:Clayton
RobertsonThe Trout GroupEmail: crobertson@troutgroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024